We’ve written a lot about ongoing clinical trials testing NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Reviews) for Parkinson’s patients. Fortunately, Chromadex (NR sellers) CEO Rob Fried gave the following update on those trials at an investor conference earlier this week:

At the 9:30 mark:

CHROMADEX CEO FRIED:

“As I said, there have been 30 published clinical studies (on NR).

The initial studies were mostly on safety.

And then they were on NAD levels.

Now, they’re into much more therapeutic indications.

Most notable one is probably Parkinson’s disease — which is a very important age related disorder.

There’s not many approved drugs on the market.

We’ve had 2 Phase 1 clinical studies that have proved safety — and the fact that it elevates NAD.

But, at secondary endpoints, both of those studies measured key Parkinson’s markers and showed a statistically significant benefit.

We are now over 3 years into a 4 year Phase 2 clinical study with 400 Parkinson’s participants who are taking 1 gram of Tru Niagen (NR) a day for a year.

That study should be completed at the end of this year.

And, sometime in the middle of next year, we should see the blinded data.

But we’re very, very hopeful about that”

At the 31:30 mark:

HOST:

“When can we expect the Phase 2 Parkinson’s data?

CHROMADEX CEO FRIED:

“We think the study will be completed in December or January.

It’s blinded.

It’ll take a few months.

I expect that we’ll be presented the data sometime in the middle of next year.

When it goes public, that’ll be between the researchers and Chromadex — whether they want to publicly present them in some form prior to a publication.

And we don’t know the answer to that yet.

But the study will be done in less than a year.

Related:

FOLLOW us on Twitter @RaisingNAD